A
AusperBio
Oligonucleotide therapeutics aiming for functional cure of chronic hepatitis B
About AusperBio
AusperBio is a near-commercial biopharmaceutical company developing targeted oligonucleotide therapeutics for chronic hepatitis B (CHB) and related diseases, with operations in the United States and China. Co-founded in 2019 by CEO Dr. Guofeng Cheng and CSO Dr. Chris Yang, it builds on the proprietary Med-Oligo™ antisense oligonucleotide (ASO) platform and Au-HALO™ targeted delivery technology. Lead candidate AHB-137 is an investigational unconjugated ASO designed to suppress HBsAg, inhibit viral DNA replication and support immune reactivation toward functional cure; it has advanced through global Phase 1 and multiple Phase 2 studies and is in a Phase 3 registrational program in China, with Breakthrough Therapy Designation from China’s CDE. AHB-171 is an investigational hepatocyte-targeted siRNA for CHB on the Au-HALO™ platform. In August 2026 AusperBio closed a $120 million Series C led by a leading strategic investor, with new investor RA Capital and returning HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments, bringing capital raised since 2024 to $360 million to advance AHB-137 toward potential commercialization, accelerate AHB-171 and combination approaches, and expand the oligonucleotide pipeline. Sources: PR Newswire 27 Aug 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Hangzhou, China
- Open positions
- None listed
- Dealroom signal
- 59.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Drug Development, Infections and Infectious Diseases, Genetics and genomics, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2025 | $63M | $252M | Genesis Capital · YuanBio Venture Capital · Sherpa Capital · CDH Investments | ↗ |
| SERIES BOther financing | May 2025 | $50M | $365M | Sherpa Capital · CDH Investments · Qiming Venture Partners · YuanBio Venture Capital | ↗ |
Growth signals
Latest recorded traffic for AusperBio is 770 monthly website visits, down 40.8% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
InnoPinnacle Fund
Series A6 investors entered at this stage
Genesis Capital- YCYuanBio Venture Capital
Hankang Capital
Qiming Venture Partners
CDH Investments
Sherpa Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AusperBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AusperBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.